Toward transcriptional therapies for the failing heart: Chemical screens to modulate genes

Timothy A. McKinsey, Eric N. Olson

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.

Original languageEnglish (US)
Pages (from-to)538-546
Number of pages9
JournalJournal of Clinical Investigation
Volume115
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Gene Expression
Sudden Death
Muscle Cells
Hypertrophy
Genes
Chromatin
Signal Transduction
Transcription Factors
Heart Failure
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Toward transcriptional therapies for the failing heart : Chemical screens to modulate genes. / McKinsey, Timothy A.; Olson, Eric N.

In: Journal of Clinical Investigation, Vol. 115, No. 3, 03.2005, p. 538-546.

Research output: Contribution to journalArticle

@article{29de63b48fa44e25ad52c728375ac3f2,
title = "Toward transcriptional therapies for the failing heart: Chemical screens to modulate genes",
abstract = "In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.",
author = "McKinsey, {Timothy A.} and Olson, {Eric N.}",
year = "2005",
month = "3",
doi = "10.1172/JCI200524144",
language = "English (US)",
volume = "115",
pages = "538--546",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Toward transcriptional therapies for the failing heart

T2 - Chemical screens to modulate genes

AU - McKinsey, Timothy A.

AU - Olson, Eric N.

PY - 2005/3

Y1 - 2005/3

N2 - In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.

AB - In response to acute and chronic stresses, the heart frequently undergoes a remodeling process that is accompanied by myocyte hypertrophy, impaired contractility, and pump failure, often culminating in sudden death. The existence of redundant signaling pathways that trigger heart failure poses challenges for therapeutic intervention. Cardiac remodeling is associated with the activation of a pathological gene program that weakens cardiac performance. Thus, targeting the disease process at the level of gene expression represents a potentially powerful therapeutic approach. In this review, we describe strategies for normalizing gene expression in the failing heart with small molecules that control signal transduction pathways directed at transcription factors and associated chromatin-modifying enzymes.

UR - http://www.scopus.com/inward/record.url?scp=14644431730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644431730&partnerID=8YFLogxK

U2 - 10.1172/JCI200524144

DO - 10.1172/JCI200524144

M3 - Article

C2 - 15765135

AN - SCOPUS:14644431730

VL - 115

SP - 538

EP - 546

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -